SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for- Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's ...

About 303 Study 303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical C ...

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines [3] - The company will have its CEO, Markus Warmuth, participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 [1][2] Company Overview - Monte Rosa is developing highly selective MGD medicines aimed at treating serious diseases in oncology, autoimmune, and inflammatory disease areas [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with unprecedented selectivity [3] - Monte Rosa has established a global license agreement with Novartis for VAV1-directed molecular glue degraders and a strategic collaboration with Roche to develop MGDs for cancer and neurological diseases [3]

SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that ...

Core Insights - Generation Bio Co. is focused on developing innovative therapeutics for T cell-driven autoimmune diseases [3] - The company will present at the Jefferies Global Healthcare Conference on June 4, 2025 [1] - A live webcast of the presentation will be available on the company's investor website [2] Company Overview - Generation Bio is developing redosable therapeutics that aim to reprogram T cells in vivo to combat autoimmune diseases [3] - The company utilizes cell-targeted lipid nanoparticles (ctLNP) for selective delivery of small interfering RNA (siRNA) to T cells [3] - This approach targets historically undruggable genes associated with autoimmune diseases, potentially unlocking new treatment avenues [3]

Core Insights - Y-mAbs Therapeutics, Inc. is focused on developing and commercializing novel radiopharmaceuticals and antibody-based therapeutic products for cancer treatment, with a virtual R&D update scheduled to highlight progress in its Radiopharmaceutical Business Unit [1][2] Radiopharmaceutical R&D Update Highlights - The GD2-SADA Phase 1 Clinical Trial (Trial 1001) has completed Part A, demonstrating that GD2-SADA is safe, tolerable, and capable of achieving targeted in vivo conjugation of Lu-DOTA [3][4] - The company plans to initiate a Trial 1001 Bridge study (Part 2A) with an optimized Radiohapten, "Proteus," in the first half of 2026, with data readout expected in the second half of 2026 [3][12] - Part B of Trial 1001 is anticipated to start in the first half of 2027, with data readout expected in the second half of 2027 [3][12] Clinical Trial Details - The primary objective of Trial 1001 is to evaluate the safety and tolerability of GD2-SADA in patients with recurrent or refractory metastatic solid tumors, including small cell lung cancer and high-risk neuroblastoma [4] - In Part A, 22 patients were dosed, with nine patients showing positive GD2 expression and eligible for the therapeutic stage of the study [4] - Results indicated that the GD2-SADA Protein clearance rate is reliably correlated to dose concentrations, providing a roadmap for tailoring the clearance interval prior to isotope administration [4][5] Safety and Tolerability - Both GD2-SADA and Lu-DOTA administrations were generally safe and well-tolerated, with no treatment-related serious adverse events reported [5] Expanded Development Pipeline - Y-mAbs has selected lung cancer, women's cancers, and gastrointestinal cancers as target areas for its expanded oncology franchise [7] - The company plans to file an IND for its first molecular imaging asset by the end of 2025 [7] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company with a focus on novel radioimmunotherapy and antibody-based therapeutic cancer products, including the FDA-approved anti-GD2 therapy DANYELZA [9]

Company announcement No. 14/2025 28 May 2025 Netcompany Group A/S ("Netcompany") hereby announces the following notification received pursuant to section 38 of the Danish Capital Markets Act from Danske Bank A/S, regarding their direct and indirect holdings and voting rights in Netcompany. On 27 May 2025 Danske Bank A/S informed Netcompany, that Danske Bank A/S on 14 March 2023 directly and indirectly via Danica Pension Livsforsikringsaktieselskab, Investeringsforeningen DI, Investeringsforeningen DI Sele ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program----Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone-- --Enobosarm 3mg added to semaglut ...

Core Viewpoint - Hyperscale Data, Inc. plans to purchase up to $10 million in XRP to enhance its financial services division through its subsidiary Ault Capital Group, Inc. [1][2] Group 1: Acquisition of XRP - ACG intends to acquire XRP, which will be classified as a crypto asset on the Company's balance sheet at fair value [1] - The acquisition is part of a broader strategy to expand into financial services, including cryptocurrency-based products and tokenization of real-world assets [2][3] - The Company believes that acquiring XRP will enhance liquidity and provide infrastructure support for blockchain-enabled financial products [3] Group 2: Financial Services Expansion - ACG has been successful in the lending business for the past four years and is now looking to broaden its services [2] - The Company aims to leverage XRP for cross-border settlements, real-time payment systems, and decentralized financial applications [3] - This strategic move is seen as a significant step towards integrating modern digital asset solutions into ACG's financial services model [3] Group 3: Future Plans and Divestiture - Hyperscale Data plans to divest ACG by December 31, 2025, focusing solely on data center operations and high-performance computing services thereafter [7] - Until the divestiture, the Company will continue to provide various mission-critical products across multiple industries through ACG [7] - The divestiture will involve an exchange of Series F Preferred Stock for shares of ACG, allowing stockholders to become ACG shareholders [8]

Core Insights - Goliath Resources Limited is initiating its largest drill campaign to date, focusing entirely on the Surebet high-grade gold discovery, with a total of 40,000 meters planned for 2025 [6][7] - The 2025 drill program aims to systematically outline the geometry and extent of the Surebet discovery, which remains open for expansion in all directions [5][6] - The company has significantly increased its land package from 66,608 hectares to 91,518 hectares, controlling 56 kilometers of the Red Line geological trend, enhancing its exploration potential [15] Drilling Program Details - The 2025 drill campaign will utilize 9 rigs and will include testing for the Motherlode causative intrusive gold source and 13 potential Eocene intrusive granitoid dykes that have not been previously tested [5][6] - Infill drilling will focus on increasing the density of pierce points in known veins, particularly in high-grade areas from the Bonanza Zone and Surebet Zone intersection [6][7] - The company has drilled a total of 92,000 meters from 2021 to 2024, resulting in over 400 pierce points that have improved the understanding of the Surebet mineralized system [6][15] Geological Insights - Recent studies indicate that there are two temperature regimes responsible for gold mineralization, suggesting a primary and secondary gold enrichment where veins and dykes intersect [7] - The Surebet discovery has predictable continuity and excellent metallurgy, with gold recoveries from gravity and flotation at 92.2%, including 48.8% free gold from gravity alone [9][15] - Four new mineralized shear zones were identified in 2024, significantly increasing the potential tonnage of the system, which remains open [15] Infrastructure and Location - The Golddigger Property is strategically located within 3 kilometers of the Red Line in the Golden Triangle of British Columbia, an area known for hosting significant mines [8] - The property is accessible by tidewater with direct barge access to Prince Rupert, and is close to communities with necessary infrastructure [10][11] Collaborative Research - Goliath Resources is a member of the Center to Advance the Science of Exploration to Reclamation in Mining (CASERM), which supports research aimed at improving geoscience data acquisition and decision-making in mining [12][16]